Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | TGTX |
---|---|---|
09:32 ET | 25482 | 29.58 |
09:33 ET | 5300 | 29.8864 |
09:35 ET | 4833 | 29.68 |
09:37 ET | 5459 | 30 |
09:39 ET | 18950 | 30.1 |
09:42 ET | 12767 | 29.975 |
09:44 ET | 10110 | 30.0245 |
09:46 ET | 15643 | 29.875 |
09:48 ET | 2407 | 29.85 |
09:50 ET | 10777 | 29.9675 |
09:51 ET | 52232 | 29.755 |
09:53 ET | 9339 | 29.77 |
09:55 ET | 23184 | 29.8799 |
09:57 ET | 5780 | 30 |
10:00 ET | 15777 | 29.95 |
10:02 ET | 7576 | 29.71 |
10:04 ET | 6928 | 29.7594 |
10:06 ET | 5405 | 29.6 |
10:08 ET | 9084 | 29.5432 |
10:09 ET | 6668 | 29.733 |
10:11 ET | 12262 | 29.7 |
10:13 ET | 6315 | 29.62 |
10:15 ET | 3049 | 29.59 |
10:18 ET | 6228 | 29.7 |
10:20 ET | 4574 | 29.6925 |
10:22 ET | 1100 | 29.685 |
10:24 ET | 3633 | 29.65 |
10:26 ET | 4320 | 29.77 |
10:27 ET | 3414 | 29.76 |
10:29 ET | 1700 | 29.775 |
10:31 ET | 6503 | 29.645 |
10:33 ET | 5824 | 29.645 |
10:36 ET | 4824 | 29.56 |
10:38 ET | 7049 | 29.66 |
10:40 ET | 3825 | 29.6159 |
10:42 ET | 4110 | 29.65 |
10:44 ET | 2428 | 29.565 |
10:45 ET | 5451 | 29.56 |
10:47 ET | 4048 | 29.52 |
10:49 ET | 2702 | 29.6 |
10:51 ET | 8956 | 29.655 |
10:54 ET | 4300 | 29.57 |
10:56 ET | 7493 | 29.57 |
10:58 ET | 6396 | 29.5599 |
11:00 ET | 2821 | 29.55 |
11:02 ET | 5048 | 29.545 |
11:03 ET | 5509 | 29.525 |
11:05 ET | 8268 | 29.56 |
11:07 ET | 8654 | 29.635 |
11:09 ET | 8742 | 29.59 |
11:12 ET | 4121 | 29.65 |
11:14 ET | 7941 | 29.73 |
11:16 ET | 8965 | 29.73 |
11:18 ET | 6909 | 29.8 |
11:20 ET | 4838 | 29.885 |
11:21 ET | 17642 | 29.7 |
11:23 ET | 3957 | 29.81 |
11:25 ET | 5725 | 29.855 |
11:27 ET | 3831 | 29.8 |
11:30 ET | 16963 | 29.97 |
11:32 ET | 10408 | 30.03 |
11:34 ET | 15161 | 30.005 |
11:36 ET | 3402 | 29.985 |
11:38 ET | 4455 | 30.01 |
11:39 ET | 4176 | 30.025 |
11:41 ET | 16997 | 30.11 |
11:43 ET | 5912 | 29.915 |
11:45 ET | 5253 | 29.88 |
11:48 ET | 22077 | 29.71 |
11:50 ET | 10695 | 29.81 |
11:52 ET | 5081 | 29.86 |
11:54 ET | 1400 | 29.82 |
11:56 ET | 1300 | 29.77 |
11:57 ET | 4078 | 29.84 |
11:59 ET | 7306 | 29.78 |
12:01 ET | 4681 | 29.77 |
12:03 ET | 3667 | 29.7848 |
12:06 ET | 2581 | 29.72 |
12:08 ET | 7091 | 29.72 |
12:10 ET | 5868 | 29.67 |
12:12 ET | 3696 | 29.73 |
12:14 ET | 2116 | 29.82 |
12:15 ET | 1430 | 29.82 |
12:17 ET | 10887 | 29.8099 |
12:19 ET | 2000 | 29.81 |
12:21 ET | 2750 | 29.75 |
12:24 ET | 900 | 29.695 |
12:26 ET | 3797 | 29.7606 |
12:28 ET | 1200 | 29.79 |
12:30 ET | 3205 | 29.81 |
12:32 ET | 824 | 29.8 |
12:33 ET | 3023 | 29.85 |
12:35 ET | 7837 | 29.83 |
12:37 ET | 3500 | 29.82 |
12:39 ET | 2075 | 29.85 |
12:42 ET | 4414 | 29.78 |
12:44 ET | 3424 | 29.81 |
12:46 ET | 2436 | 29.825 |
12:48 ET | 2025 | 29.78 |
12:50 ET | 2150 | 29.74 |
12:51 ET | 8719 | 29.89 |
12:53 ET | 2369 | 29.9356 |
12:55 ET | 1974 | 29.9 |
12:57 ET | 1416 | 29.8364 |
01:00 ET | 1606 | 29.835 |
01:02 ET | 2022 | 29.83 |
01:04 ET | 3085 | 29.8136 |
01:06 ET | 1500 | 29.76 |
01:08 ET | 1896 | 29.73 |
01:09 ET | 2911 | 29.8 |
01:11 ET | 2274 | 29.8 |
01:13 ET | 4019 | 29.805 |
01:15 ET | 1679 | 29.75 |
01:18 ET | 12582 | 29.73 |
01:20 ET | 5841 | 29.67 |
01:22 ET | 1700 | 29.68 |
01:24 ET | 5257 | 29.61 |
01:26 ET | 22923 | 29.6236 |
01:27 ET | 5300 | 29.56 |
01:29 ET | 10725 | 29.7 |
01:31 ET | 1600 | 29.665 |
01:33 ET | 9953 | 29.725 |
01:36 ET | 2600 | 29.73 |
01:38 ET | 4149 | 29.85 |
01:40 ET | 9700 | 29.85 |
01:42 ET | 7889 | 29.945 |
01:44 ET | 2701 | 29.82 |
01:45 ET | 3464 | 29.82 |
01:47 ET | 2933 | 29.87 |
01:49 ET | 4298 | 29.8658 |
01:51 ET | 2826 | 29.8 |
01:54 ET | 2860 | 29.875 |
01:56 ET | 1200 | 29.9154 |
01:58 ET | 1935 | 29.89 |
02:00 ET | 700 | 29.89 |
02:02 ET | 4664 | 29.95 |
02:03 ET | 4982 | 29.9 |
02:05 ET | 1274 | 29.9 |
02:07 ET | 4907 | 29.91 |
02:09 ET | 3966 | 29.94 |
02:12 ET | 2614 | 29.91 |
02:14 ET | 4126 | 29.96 |
02:16 ET | 8323 | 29.99 |
02:18 ET | 1500 | 29.97 |
02:20 ET | 4300 | 30 |
02:21 ET | 5100 | 30.02 |
02:23 ET | 5693 | 29.94 |
02:25 ET | 2303 | 29.98 |
02:27 ET | 3250 | 29.965 |
02:30 ET | 5979 | 29.99 |
02:32 ET | 1834 | 29.97 |
02:34 ET | 2558 | 29.94 |
02:36 ET | 1000 | 29.91 |
02:38 ET | 7264 | 29.915 |
02:39 ET | 12912 | 29.83 |
02:41 ET | 10399 | 29.89 |
02:43 ET | 700 | 29.815 |
02:45 ET | 901 | 29.79 |
02:48 ET | 7548 | 29.76 |
02:50 ET | 11364 | 29.77 |
02:52 ET | 2999 | 29.72 |
02:54 ET | 3536 | 29.75 |
02:56 ET | 4199 | 29.73 |
02:57 ET | 2900 | 29.72 |
02:59 ET | 20294 | 29.68 |
03:01 ET | 7581 | 29.67 |
03:03 ET | 15527 | 29.6299 |
03:06 ET | 14033 | 29.68 |
03:08 ET | 4780 | 29.71 |
03:10 ET | 9052 | 29.765 |
03:12 ET | 10798 | 29.795 |
03:14 ET | 5946 | 29.76 |
03:15 ET | 5713 | 29.795 |
03:17 ET | 3400 | 29.835 |
03:19 ET | 12555 | 29.831 |
03:21 ET | 10587 | 29.895 |
03:24 ET | 3290 | 29.905 |
03:26 ET | 5559 | 29.84 |
03:28 ET | 5454 | 29.89 |
03:30 ET | 10399 | 29.935 |
03:32 ET | 4500 | 29.93 |
03:33 ET | 9890 | 29.92 |
03:35 ET | 5105 | 30.02 |
03:37 ET | 7646 | 29.96 |
03:39 ET | 7270 | 30.05 |
03:42 ET | 23206 | 30.031 |
03:44 ET | 20010 | 30.06 |
03:46 ET | 7791 | 30.11 |
03:48 ET | 16229 | 30.033 |
03:50 ET | 10196 | 30.09 |
03:51 ET | 20144 | 30.11 |
03:53 ET | 16323 | 30.2 |
03:55 ET | 18743 | 30.18 |
03:57 ET | 26361 | 30.28 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
TG Therapeutics Inc | 4.6B | -283.8x | --- |
ADMA Biologics Inc | 4.6B | 74.4x | --- |
Axsome Therapeutics Inc | 4.4B | -14.6x | --- |
Arcellx Inc | 4.7B | -121.5x | --- |
Blueprint Medicines Corp | 5.7B | -44.9x | --- |
CRISPR Therapeutics AG | 4.0B | -16.8x | --- |
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.6B |
---|---|
Revenue (TTM) | $264.8M |
Shares Outstanding | 154.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.19 |
EPS | $-0.11 |
Book Value | $1.06 |
P/E Ratio | -283.8x |
Price/Sales (TTM) | 17.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -0.19% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.